Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
AZ 10397767 is a potent CXCR2 antagonist (IC50 = 1 nM); attenuates oxaliplatin-induced NF-κB activation, increases oxaliplatin cytotoxicity, and potentiates oxaliplatin-induced apoptosis in AIPC cells. Reduces the numbers of neutrophils infiltrating into tumors in both in vitro and in vivo models and delayed tumor growth. Orally bioavailable.
AZ 10397767 is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Antiviral Library. Find out more about compound libraries available from Tocris.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 400.88. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.49 mL||12.47 mL||24.95 mL|
|5 mM||0.5 mL||2.49 mL||4.99 mL|
|10 mM||0.25 mL||1.25 mL||2.49 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the biological activity of the product.
Wilson et al (2008) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxalip. through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J.Pharmacol.Exp.Ther. 327 746 PMID: 18780829
Walters et al (2008) Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg.Med.Chem.Lett. 18 798 PMID: 18240390
Tazzyman et al (2011) Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth. Int.J.Cancer 129 847 PMID: 21328342
If you know of a relevant reference for AZ 10397767, please let us know.
Keywords: AZ 10397767, AZ 10397767 supplier, AZ10397767, chemokine, cxc, receptors, antagonists, antagonism, orally, bioavailable, potent, selective, Chemokine, CXC, Receptors, 5872, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for AZ 10397767. Do you know of a great paper that uses AZ 10397767 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review AZ 10397767 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.